Assembly Biosciences (NASDAQ:ASMB) Shares Gap Up – Should You Buy?

Assembly Biosciences, Inc. (NASDAQ:ASMB)’s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $30.01, but opened at $32.88. Assembly Biosciences shares last traded at $32.8750, with a volume of 4,670 shares changing hands.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on ASMB. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Assembly Biosciences in a research report on Tuesday. Wall Street Zen downgraded Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. Mizuho set a $45.00 target price on Assembly Biosciences and gave the stock an “outperform” rating in a report on Monday, June 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Friday, July 17th. Finally, Guggenheim reiterated a “buy” rating and issued a $43.00 price objective on shares of Assembly Biosciences in a report on Thursday, May 28th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Assembly Biosciences presently has an average rating of “Moderate Buy” and a consensus target price of $44.00.

Assembly Biosciences Trading Up 1.8%

The business’s 50 day moving average price is $26.43 and its two-hundred day moving average price is $27.44. The company has a market capitalization of $520.08 million, a price-to-earnings ratio of 32.24 and a beta of 1.10.

Assembly Biosciences (NASDAQ:ASMB) last posted its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.52. Assembly Biosciences had a negative return on equity of 0.02% and a negative net margin of 0.06%.The firm had revenue of $13.37 million during the quarter, compared to the consensus estimate of $8.60 million. Analysts expect that Assembly Biosciences, Inc. will post 1.9 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ASMB. Bank of New York Mellon Corp bought a new stake in shares of Assembly Biosciences in the 2nd quarter valued at $660,000. Bank of America Corp DE increased its holdings in shares of Assembly Biosciences by 113.3% during the first quarter. Bank of America Corp DE now owns 10,902 shares of the biopharmaceutical company’s stock valued at $303,000 after acquiring an additional 5,792 shares in the last quarter. Stempoint Capital LP raised its holdings in Assembly Biosciences by 18.3% during the first quarter. Stempoint Capital LP now owns 185,435 shares of the biopharmaceutical company’s stock worth $5,146,000 after buying an additional 28,707 shares during the last quarter. Janus Henderson Group PLC increased its holdings in Assembly Biosciences by 1.4% during the 1st quarter. Janus Henderson Group PLC now owns 849,309 shares of the biopharmaceutical company’s stock worth $23,479,000 after purchasing an additional 11,384 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Assembly Biosciences by 69.4% in the 1st quarter. Renaissance Technologies LLC now owns 15,651 shares of the biopharmaceutical company’s stock worth $434,000 after acquiring an additional 6,411 shares in the last quarter. 19.92% of the stock is owned by institutional investors and hedge funds.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.